Recursion Pharmaceuticals Earnings
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 4.34 -0.46%
Next earnings date
Wed, Nov 4, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.24
Recursion Pharmaceuticals earnings summary
Recursion Pharmaceuticals is scheduled to report Sep/2026 earnings on Nov 4, 2026, with analysts expecting EPS of $-0.24. In its most recent report on Aug 5, 2026 (Q2 2026), RXRX posted EPS of $-0.25. Revenue for the quarter was $7.7 million.
Across the last 16 reports, RXRX shares moved an average of 12.3% (in either direction) in the first trading session after results, rising 6 times and falling 10 times.
Summary generated from market data by MetaCap's automated system. Methodology
RXRX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $-0.25 | — | -1.9% |
| May 6, 2026 | — | $-0.22 | — | -11.7% |
| Feb 25, 2026 | — | $-0.17 | — | -5.7% |
| Nov 5, 2025 | — | $-0.36 | — | -10.4% |
| Aug 5, 2025 | — | $-0.41 | — | +7.6% |
| May 5, 2025 | — | $-0.50 | — | +5.3% |
| Feb 28, 2025 | — | $-0.56 | — | -12.3% |
| Nov 6, 2024 | — | $-0.34 | — | -13.0% |
| Aug 8, 2024 | — | $-0.40 | — | +7.2% |
| May 9, 2024 | — | $-0.39 | — | +9.5% |
| Feb 29, 2024 | — | $-0.43 | — | -12.6% |
| Nov 9, 2023 | — | $-0.43 | — | +29.1% |
| Aug 8, 2023 | — | $-0.38 | — | -10.3% |
| May 8, 2023 | — | $-0.34 | — | +21.6% |
| Feb 27, 2023 | — | $-0.30 | — | -16.6% |
| Nov 8, 2022 | — | $-0.35 | — | -21.3% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.